Salt Lake City, Utah, February 16, 2017 – ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced […]
January 15, 2017
Happy New Year from ProLung!
2016 has been a spectacular year.
To achieve our research goals more rapidly, we assembled the most extensive team of clinical investigators of lung cancer in pulmonology.
This speeds the […]
Steven C. Eror, President and CEO, meets with Gregory C. Simon, White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.
San Francisco, California, Wednesday October 19, 2016
ProLungDX seeks funds for cancer test; sees eventual IPO – CEO
ProLungDX, a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US […]
ProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer
Salt Lake City, UT, USA, October 13, 2016 – ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, […]
Salt Lake City, UT, USA, September 7, 2016 – ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, […]
Lung cancer survival rate increases by 73% if caught early
A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found
that patients with a high risk of
developing lung cancer can be identified
with early stage disease […]
Salt Lake City, Utah, May 25, 2016 – The Board of Directors of Fresh Medical Laboratories Inc., doing business as ProLungdx, today announced the appointment of Dr. John C. Ruckdeschel, M.D. to serve as […]
Salt Lake City, Utah, May 19, 2016 – Fresh Medical Laboratories, Inc, doing business as ProLungdx™, announced today that its board has appointed Todd Morgan as Chairman of the Board of Directors. Mr. Morgan […]
Salt Lake City, Utah, USA, May 18, 2016 – Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry. When the Electro Pulmonary Nodule […]
September 22, 2015, Salt Lake City, Utah – A study comparing results from the ProLung EPN scan to the results of PET scans was presented at the 16th World Conference on Lung Cancer in Denver, […]
August 20, 2015, Salt Lake City Utah – The Board of Directors of the Company appointed Jeffrey S. O’Driscoll as a director of the Company. Dr. O’Driscoll has practiced as an emergency physician since 1992. He started […]
Salt Lake City, Utah (July 2, 2014) – “Rich McKeown brings a deep understanding of the healthcare industry as the chief executive of one of the nation’s most respected healthcare consulting firms,” said ProLung President […]
September 11, 2012, Salt Lake City, Utah—The medical technology company, ProLung, today announced the naming current board member Clark A. Campbell, Ph.D. as its new Chairman, replacing William A. Fresh, who continues as a Director. Campbell steps into this role as the company makes preparations to market the ProLung Test, a new tool in the early detection of lung cancer. Studies have shown that the test immediately and accurately identifies malignancy in patients who have been found to have an indeterminate lung mass. This can help solve the crucial problem of late detection, a major factor in lung cancer’s high mortality rate. “Dr. Campbell’s project management expertise will be invaluable as we embark on the final stages of preparing the ProLung Test for U.S. and international markets,” said Steven C. Eror, president and CEO of ProLung. “We’re fortunate to have him join us in our efforts to help give lung cancer patients a better chance for survival.”
September 11, 2012, Salt Lake City, Utah—Freshmedx today announced its intention to do business as ProLung, as it continues to commercialize the ProLung Test, a new tool in the early detection of lung cancer. According to company president Steven C. Eror, “The ProLung name expresses the hope this new test brings to the battle against the deadliest of all cancers. Studies have shown this new technology to be a major step forward in helping to solve the problems of late detection and difficult diagnosis, the main causes of lung cancer’s high mortality rate. ProLung reflects our commitment to promote lung health and improve outcomes for lung cancer patients.”
March 22, 2011— Freshmedx today announced the completion of a clinical trial at a major medical center in Baltimore. Freshmedx’s proprietary Computerized Bioconductance Test (CB TestTM) showed favorable results in distinguishing between benign and […]
Freshmedx study published in the Journal of Thoracic Oncology, the official Journal of the International Association for the Study of Lung Cancer
March 20, 2012— Freshmedx today announced that its ground-breaking study on the use of computed bioconductance technology in detecting lung cancer will be published in April edition of the Journal of Thoracic Oncology. Freshmedx’s proprietary CB Test is a non- invasive adjunctive test that can evaluate patients with lesions suspicious for lung cancer and evaluate the likelihood that indeterminate lung lesions are malignant or benign. “We are pleased to have our clinical results published in the leading lung cancer journal,” said Steve Eror, president and chief executive officer of Freshmedx. “There is an increased need for this technology, especially given the recent National Lung Screening Trial (NLST) results and the adoption of Low-dose helical CT Screening (LDCT) programs.”
February 18, 2010—In celebration of World Cancer Day and the Year of the Lung, Freshmedx today announced that it has entered into multiple discussions for the international license of its Bioconductance Scanning Platform (BSP). The BSP is a medical device that can dramatically improve the accuracy of pre-surgical lung cancer diagnosis in a simple and painless 12-minute scan. Freshmedx is pursuing regulatory approvals in the US and has completed CE mark testing for European distribution. Cancer is projected to become the leading cause of death in 2010 according to the International Agency for Research on Cancer. Of all cancers, lung cancer is by far the most deadly. It results in more deaths than breast, prostate, colon, liver, kidney and melanoma cancers combined, yet it receives only one tenth the per-patient resources of other cancers.